Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Pathways (CLPA) -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (351)	12/31/1999 11:37:00 PM
From: Neuroguy	Read Replies (1) \| Respond to of 566

Tuck - Celebrex approval. The approval of Celebrex for FAP nicely telegraphs the standards ODAC are willing to accept for a drug in this indication. Since Aptosyn is about twice as potent with far better safety data, we should breeze through the FDA process, albeit a little later than hoped for. However, Searle have no completed trials on any other cancer indication and we have good results from a PIII prostate trial already in hand. So despite getting off the blocks behind a big pharma, our off-label sales should be good, perhaps better than theirs. The PIII sporadic polyps trial completes in March also, which is a significant market. A second prostate trial may have completed by then too. So we should be in very solid shape towards the end of Q1. We're actually in very solid shape now, though thanks to the massive short position (~32%) you wouldn't know it from the charts! Best wishes in the new Millennium to all.